Bridgeway Capital Management Inc. purchased a new position in Jounce Therapeutics Inc (NASDAQ:JNCE) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 203,300 shares of the company’s stock, valued at approximately $1,321,000. Bridgeway Capital Management Inc. owned approximately 0.62% of Jounce Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds and other institutional investors have also modified their holdings of the business. BlackRock Inc. boosted its holdings in Jounce Therapeutics by 4.0% in the third quarter. BlackRock Inc. now owns 1,450,680 shares of the company’s stock worth $9,429,000 after acquiring an additional 55,775 shares in the last quarter. Redmile Group LLC lifted its holdings in shares of Jounce Therapeutics by 2.7% during the second quarter. Redmile Group LLC now owns 1,214,593 shares of the company’s stock worth $9,304,000 after purchasing an additional 32,200 shares during the period. Millennium Management LLC lifted its holdings in shares of Jounce Therapeutics by 91.6% during the second quarter. Millennium Management LLC now owns 679,177 shares of the company’s stock worth $5,202,000 after purchasing an additional 324,681 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Jounce Therapeutics by 153.0% during the third quarter. JPMorgan Chase & Co. now owns 440,029 shares of the company’s stock worth $2,861,000 after purchasing an additional 266,126 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Jounce Therapeutics by 37.8% during the third quarter. Dimensional Fund Advisors LP now owns 433,712 shares of the company’s stock worth $2,819,000 after purchasing an additional 118,881 shares during the period. 82.60% of the stock is owned by institutional investors and hedge funds.
JNCE has been the subject of a number of research reports. Cowen reaffirmed a “hold” rating on shares of Jounce Therapeutics in a report on Thursday, August 9th. JPMorgan Chase & Co. decreased their target price on Jounce Therapeutics from $12.00 to $10.00 and set a “hold” rating for the company in a report on Friday, August 10th. HC Wainwright set a $13.00 target price on Jounce Therapeutics and gave the stock a “buy” rating in a report on Monday, August 13th. Zacks Investment Research raised Jounce Therapeutics from a “hold” rating to a “buy” rating and set a $9.25 target price for the company in a report on Tuesday, August 14th. Finally, Raymond James decreased their target price on Jounce Therapeutics from $13.00 to $12.00 and set an “outperform” rating for the company in a report on Tuesday, October 23rd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the stock. Jounce Therapeutics currently has an average rating of “Hold” and a consensus price target of $11.92.
Jounce Therapeutics stock opened at $4.33 on Thursday. Jounce Therapeutics Inc has a 52 week low of $3.30 and a 52 week high of $29.25. The stock has a market cap of $141.27 million, a P/E ratio of -7.60 and a beta of 5.00.
Jounce Therapeutics (NASDAQ:JNCE) last released its earnings results on Tuesday, November 13th. The company reported ($0.23) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.34) by $0.11. Jounce Therapeutics had a negative return on equity of 29.58% and a negative net margin of 59.74%. The firm had revenue of $14.53 million during the quarter, compared to the consensus estimate of $12.80 million. Analysts expect that Jounce Therapeutics Inc will post -1.14 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Bridgeway Capital Management Inc. Invests $1.32 Million in Jounce Therapeutics Inc (JNCE) Stock” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/12/06/bridgeway-capital-management-inc-invests-1-32-million-in-jounce-therapeutics-inc-jnce-stock.html.
Jounce Therapeutics Profile
Jounce Therapeutics, Inc, a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform.
Read More: Benefits of owning preferred stock
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.